RS Oncology LLC
- Biotech or pharma, therapeutic R&D
RS Oncology, LLC is a clinical stage biotechnology company based in Cambridge, Massachusetts developing a portfolio of compounds that exploit disrupted metabolism and oxidative stress in aggressive cancers. Specifically, our compounds irreversibly bind and inhibit mitochondrial peroxiredoxin 3 (PRX3) resulting in the selective killing of malignant cells by upregulation of oxidative stress while sparing normal cells. These compounds are also proving to be immunomodulators. RSO's lead program recently completed its Phase 1/2 clinical trial in Malignant Pleural Mesothelioma in the United Kingdom. RSO is now reviewing and analyzing the data to develop a Phase 3 registration trial, likely in the US, UK and EU. RSO is also in the lead optimization stage for its next generation compound that will be administered systemically in all solid tumors. RSO is seeking partnerships and investors to bring its lead compound into a registration trial as well as to develop its second generation compound.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}